OR WAIT null SECS
November 12, 2020
Apeiron Biologics has selected Domainex to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b.
AstraZeneca has received approval for Calquence (acalabrutinib) to be used as a treatment of chronic lymphocytic leukemia (CLL) in adults within the European Union (EU).
PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.
Vifor Pharma and Angion Biomedica have signed a license agreement that will see the commercialization of late-stage product, ANG-3777.
Optibrium has entered into a cheminformatics collaboration with MSD (known as Merck & Co. in the United States).
November 11, 2020
Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021.
The companies will initially develop and design process technologies, single-use systems, and automation, with plans to eventually focus on an expanding process and digital technologies to optimize a continuous manufacturing process.
November 06, 2020
ProteoNic has licensed its protein expression technology, 2G UNic, to Gilead Sciences.
ACG has acquired a significant stake in IQGEN-X, a Mumbai-based start-up contract research organization (CRO).
Lonza has inaugurated its first ADC payload manufacturing suite at the Visp, Switzerland site.